Oncology

SARAH CANNON RESEARCH INSTITUTE (SCRI)
OUR ONCOLOGY FOCUS

Advancing Therapies for Patients

SCRI, an industry leader in clinical trials, is dedicated to advancing therapies for patients through clinical research. SCRI conducts the largest community-based research program in the nation, including clinical trials in 10 therapeutic areas through its affiliation with a powerful network of hundreds of physicians. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites across the country.

Our work—SCRI is a strategic research organization that sponsors oncology clinical trials through its affiliation with clinical oncology practices throughout the country. This work makes it possible for thousands of cancer patients to participate in research studies close to home.
Our services to physician investigators and industry—SCRI provides research support services to oncologists, hematologists and drug development sponsors across the country.

Our Oncology Roots

In the fall of 2004, SCRI was formed by Hospital Corporation of America (HCA) and Tennessee Oncology. As community healthcare providers, both investors share a long-term vision and commitment to advance treatment through clinical research. HCA has hundreds of community hospitals and surgery centers worldwide. Tennessee Oncology is considered the oncology market leader in the mid South.

Prior to forming SCRI, Tennessee Oncology had long been working with a national network of its peers to answer important research questions and advance new treatments for patients. SCRI was formed with the idea that new drugs and therapies could be brought to more doctors and patients in a community setting.

Our Oncology Research

For the drug development industry, a relationship with SCRI offers:

Access to a broad and diverse mix of patients.
Experienced, proven investigators and research-focused sites.
Efficient, effective clinical trial management services.
Access to some of the world’s scientific thought leaders.

SCRI has relationships with multiple pharmaceutical and biotechnology companies, resulting from delivered value in the drug development process. Our portfolio of clinical trial management services facilitates rapid and cost effective study completion.

Participation in the SCRI clinical trials program enables community-based oncology practices to:

Offer patients a larger and varied menu of clinical trials and advanced treatment options.
Concentrate on the care and treatment of research patients, while delegating the site support services.
Produce quality research data that complies with all applicable regulations and guidelines

SCRI Global Services

SCRI Global Services is a division of the Sarah Cannon Research Institute that specializes in clinical research services with a focus on oncology drug development programs.

Relationships with the nearly 500 investigators affiliated with the SCRI strategic sites and the sites in the SCRI Oncology Research Consortium, along with investigators at sites outside the SCRI Network allow SCRI Global Services to offer sponsors access to a diverse and varied patient population spanning multiple tumor types and disease stages. These relationships further enhance the depth and breadth of therapeutic expertise of SCRI Global Services enabling us to provide focused and strategic operational support. This ensures clinical trials are conducted in a timely manner and reported with high-quality, registration-standard data.

We are committed to our customers’ goals, and we tailor our teams and processes to meet them. Senior-level management and clinical staff stay involved throughout our working relationship, ensuring strong science and consistent quality every step of the way. We serve as collaborators and research consultants, and we strive to provide better insights that contribute to success and discovery.

Scientific Leadership in Oncology

SCRI is unique because it focuses not only on serving the drug development industry and other principal investigators, but also on developing its own innovative SCRI-sponsored research. Through the careful work of our principal investigators (PIs) and hundreds of sub-investigators across the country, SCRI is able to offer clinical trials to thousands of individual patients, which in some cases, has changed the standard of care for all.

Highlights include:

Extensive national network with hundreds of oncologists across the country.
Affiliated sites with dedicated principal investigators, research and data management personnel.
Hundreds of investigator-initiated studies conducted since 1995.
Approximately 20,000 patients enrolled since the program’s inception in 1993.
Access to over 90,000 new cancer patients per year.
Successful Drug Development (Phase I) Program, which has conducted more than 70 first-in-man trials.
Hundreds of publications in the form of articles in peer-reviewed journals and accepted abstracts.

Program Leaders

Howard A. Burris III, M.D., Chief Medical Officer and Director, Drug Development Program
John D. Hainsworth, M.D., Chief Scientific Officer
F. Anthony Greco, M.D., Director of Sarah Cannon Cancer Center
Denise A. Yardley, M.D., Senior Investigator of Breast Cancer Research Program
David Spigel, M.D., Director of Lung Cancer Research Program
Johanna Bendell, S.B., M.D., Director, GI Cancer Research Program;Associate Director, Drug Development Program;
Jeffrey R. Infante, M.D., Associate Director, Drug Development Program
Suzanne Jones, Pharm. D., Scientific Director, Drug Development Program
Gautam Rao, M.D., Director, GYN Oncology Program
Ian W. Flinn, M.D., Director of Hematologic Malignancies Research Program, Sarah Cannon Blood and Marrow Transplant Program
Jesus G. Berdeja, M.D., Director of Leukemia Research Program, Sarah Cannon Blood and Marrow Transplant Program
Hendrik-Tobias Arkenau, M.D., Ph.D., Director, Drug Development Program, Sarah Cannon Research UK; Associate Director, Drug Development Program, Sarah Cannon Research Institute

Sarah Cannon Research Institute